Inhaled Corticosteroids + Azithromycin for Asthma
(iTREAT-PC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to find better ways to treat asthma by comparing different approaches to using inhaled steroids and azithromycin, an antibiotic. It examines how these treatments work alone and together to manage asthma symptoms and reduce flare-ups. Individuals who have had asthma for at least a year and currently use inhaled steroids, yet still experience frequent symptoms or serious flare-ups, might be suitable candidates for this trial. As a Phase 4 trial, the treatment has already received FDA approval and proven effective, and this research seeks to understand how it benefits more patients.
Do I have to stop taking my current medications to join the trial?
The trial does not specify that you must stop taking your current medications, but if you are on certain antibiotics or medications that interact with azithromycin, you may need to stop them or undergo additional monitoring. If you're on antibiotics for less than 30 days, you can join after stopping them for 72 hours.
What is the safety track record for these treatments?
Past studies have shown that inhaled corticosteroids (ICS), commonly used to treat asthma, are generally safe at low doses. Research indicates that low-dose ICS does not significantly increase the risk of serious side effects. However, moderate to high doses may slightly raise the risk of heart problems and pneumonia.
Studies have indicated that azithromycin is well-tolerated by people with asthma. Participants in these trials did not experience more side effects, such as stomach issues or skin problems, when taking azithromycin.
Although the combination of inhaled corticosteroids and azithromycin has not been extensively studied, both have shown safety when used individually. This suggests they might be safe to use together, although further research would be beneficial to confirm this.12345Why are researchers enthusiastic about this study treatment?
Researchers are excited about the combination of inhaled corticosteroids (ICS) and azithromycin for asthma because it explores a potentially enhanced approach to managing symptoms. While standard asthma treatments often rely on inhaled corticosteroids for maintenance and short-acting bronchodilators for relief, this trial investigates the use of ICS as part of rescue therapy, which could offer more immediate symptom control. Additionally, azithromycin, an antibiotic typically used to fight infections, is being considered for its anti-inflammatory properties, which might provide further benefit beyond typical asthma medications. This combination aims to improve asthma management by reducing inflammation and providing quick relief, potentially leading to better overall control of asthma symptoms.
What evidence suggests that this trial's treatments could be effective for asthma?
Research has shown that inhaled corticosteroids (ICS) effectively reduce asthma symptoms and lower the risk of severe asthma attacks. Regular use of ICS can cut the number of these attacks by more than half. In this trial, some participants will receive ICS as part of rescue therapy. Azithromycin, an antibiotic, also reduces asthma flare-ups and improves the quality of life for people with severe asthma. Another group in this trial will receive Azithromycin alone. When ICS and Azithromycin are used together, as in one of the trial arms, they significantly reduce severe asthma attacks compared to using quick-relief inhalers alone. This combination offers a promising way to better control asthma symptoms.24678
Who Is on the Research Team?
Wilson D Pace, MD, FAAFP
Principal Investigator
DARTNet Institute
Dave Mauger, PhD
Principal Investigator
Penn State University
Are You a Good Fit for This Trial?
This trial is for individuals with persistent asthma. Participants should be currently receiving primary care and willing to try new approaches to reduce asthma exacerbations (AEX). Specific eligibility criteria are not provided, but typically participants must meet certain health conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Rescue-Inhaled Corticosteroids (R-ICS), azithromycin, or a combination of both, with home monitoring of asthma symptoms
Follow-up
Participants are monitored for safety and effectiveness after treatment, with a focus on asthma exacerbations and control
Open-label extension (optional)
Participants in the azithromycin arms may opt into up to 12 additional months of follow-up after stopping azithromycin
What Are the Treatments Tested in This Trial?
Interventions
- Azithromycin
- Inhaled corticosteroid (ICS)
Trial Overview
The study compares two treatments: Rescue-Inhaled Corticosteroids (R-ICS) used during an asthma attack, and Azithromycin as a preventive therapy. It will evaluate these treatments both separately and together, using a web-based application for symptom monitoring.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Active Control
Participants will be asked to use an online Asthma Symptom Monitoring (ASM) tool to enhance communication with the medical team as well as self-awareness of their asthma symptoms. There are no "study drugs" in this intervention.
Maintenance And Reliever Therapy (MART), or Patient Activated Reliever Triggered Inhaled Corticosteroids (PARTICS) - this includes budesonide-albuterol (AirSupra)
Azithromycin - 500mg three times per week. Can be reduced to 250 mg three times per week for side effects.
R-ICS either as MART therapy or PARTICS + Azithromycin
Find a Clinic Near You
Who Is Running the Clinical Trial?
DARTNet Institute
Lead Sponsor
Reliant Medical Group
Collaborator
Icahn School of Medicine at Mount Sinai
Collaborator
University of Kansas
Collaborator
Rutgers University
Collaborator
University of Colorado, Denver
Collaborator
RAND
Collaborator
AdventHealth
Collaborator
Wake Forest University Health Sciences
Collaborator
Kelsey Research Foundation
Collaborator
Citations
Efficacy of azithromycin in severe asthma from the ...
Long-term, low-dose azithromycin reduced asthma exacerbations and improved the quality of life in patients with severe asthma, regardless of how ...
Effect of Azithromycin on Asthma Remission in Adults With ...
In this study, adults with persistent symptomatic asthma achieved a higher remission rate when treated with azithromycin. Remission on treatment ...
Effect of Azithromycin on Asthma Remission in Adults With ...
In this study, adults with persistent symptomatic asthma achieved a higher remission rate when treated with azithromycin. Remission on treatment may be an ...
4.
journals.lww.com
journals.lww.com/ebp/fulltext/2019/07000/does_the_addition_of_azithromycin_improve_outcomes.1.aspxDoes the addition of azithromycin improve outcomes in the...
There was a significant shortening of the asthma-like episode in the azithromycin group compared with placebo (3.4 vs 7.7 days; percent reduction, 63%; 95% CI, ...
Does maintenance azithromycin reduce asthma ...
Azithromycin was effective at reducing the overall rate of exacerbations in both eosinophilic and noneosinophilic asthma. However, different definitions of ...
Efficacy and safety of macrolide therapy for adult asthma
Additional treatment with azithromycin did not increase adverse events including gastrointestinal and skin symptoms in pediatric asthma in the intervention ...
The efficacy and safety of azithromycin in asthma
These findings demonstrate no beneficial clinical outcome of azithromycin in asthma control, and we propose that further prospective cohorts are warranted.
Azithromycin for Severe Asthma
Safety profile. In clinical trials assessing azithromycin treatment in people with severe asthma, treatment was generally well tolerated (2). ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.